Table 3.
In vivo efficacies of tedizolid phosphate and linezolid against S. pneumoniae (PSSP) in a murine pneumonia model according to 15-day cumulative survival rates
| Treatment | Regimen (total daily dose)a | Survival rate (%) | MSDb (day) | ED50 (mg/kg/day)c |
|---|---|---|---|---|
| Tedizolid phosphate | 2.5 mg/kg QD (2.5) | 50 | 9.7 | 2.80 (1.41–4.44) |
| 5 mg/kg QD (5) | 80 | 12.2 | ||
| 10 mg/kg QD (10) | 100 | 14.0 | ||
| 20 mg/kg QD (20) | 100 | 14.0 | ||
| Linezolid | 2.5 mg/kg BID (5) | 30 | 7.0 | 8.09 (4.74–11.91) |
| 5 mg/kg BID (10) | 70 | 11.1 | ||
| 10 mg/kg BID (20) | 90 | 13.0 | ||
| 20 mg/kg BID (40) | 100 | 14.0 | ||
| No treatment (infected control) | Not applicable | 10 | 5.7 | Not applicable |
a
Oral antimicrobial treatment was initiated at 4 h postinfection and was administered for 48 h at the indicated regimens. Total daily doses are given in milligrams per kilogram.
b
MDS, mean survival day, which is equal to [f(d − 1)]/N, where f is the number of mice recorded to have expired on day d (survivors on day 15 were included in f for that day) and N is the number of mice in a group.
c
Data in parentheses are 95% CIs.